Figure 11.1.1, Cumulative chance of being best at reducing overall mortality - Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients

Warning: The NCBI web site requires JavaScript to function. more...

Figure 11.1.1Cumulative chance of being best at reducing overall mortality

Treatment groups are carbapenem (1), ureidopenicillins (2), 3^rd Generation Cephalosporin (3), 4^th Generation Cephalosporin (4), ureidopenicillins +aminoglycoside (5), 3^rd Generation Cephalosporin +aminoglycoside (6) and 4^th Generation Cephalosporin +aminoglycoside (7).

Antibiotic Group	Median proportion best	95% Credible intervals
Ureidopenicillins	0.83	0.83 to 1
3^rd Generation Cephalosporin	0.33	0.33 to 1
Carbapenem	0.17	0.17 to 0.83
4^th Generation Cephalosporin	0	0 to 0.67
Ureidopenicillins +aminoglycoside	0	0 to 0.83
3^rd Generation Cephalosporin +aminolycoside	0	0 to 0.83
4^th Generation Cephalosporin+aminoglycoside	0	0 to 1

From: Initial Treatment: guideline chapter six

Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.

NICE Clinical Guidelines, No. 151.

National Collaborating Centre for Cancer (UK).

London: National Institute for Health and Clinical Excellence (NICE); 2012 Sep.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.